Vertex's cystic fibrosis therapy meets goal of late-stage studies
In this article:
March 6 (Reuters) - Vertex Pharmaceuticals Inc said on Wednesday its triple-combination therapy showed improvement in lung function for people with cystic fibrosis (CF).
The combination therapy - consisting its experimental agent VX-445 and its other CF drugs Kalydeco and tezacaftor - met the main goal of two late-stage studies, showing improvement in lung function.
(Reporting by Saumya Sibi Joseph and Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
